| 薛珊,宋华伟.FOLFIRI方案对胃癌患者IGF-1、VEGF、EGFR及CEA的影响分析[J].浙江中西医结合杂志,2020,30(12): |
| FOLFIRI方案对胃癌患者IGF-1、VEGF、EGFR及CEA的影响分析 |
| Analysis of the Effects of FOLFIRI regimen on IGF-1, VEGF, EGFR and CEA in patients with Gastric cancer |
| 投稿时间：2020-03-14 修订日期：2020-09-24 |
| DOI： |
| 中文关键词: FOLFIRI方案 胃癌 胰岛素样生长因子-1 血管内皮生长因子 表皮生长因子受体 癌胚抗原 |
| 英文关键词:FOLFIRI regimen Gastric cancer Insulin-like growth factor-1 Vascular endothelial growth factor Epidermal growth factor receptor Carcinoembryonic antigen |
| 基金项目:湖州市自然科学资金项目（编号：2016YZB01） |
|
| 摘要点击次数: 929 |
| 全文下载次数: 13 |
| 中文摘要: |
| 目的：分析FOLFIRI方案对胃癌患者胰岛素样生长因子-1(Insulin-like growth factor-1,IGF-1)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)、表皮生长因子受体(Epidermal growth factor receptor,EGFR)及癌胚抗原(Carcinoembryonic antigen,CEA)的影响。方法：以本院2016年1月-2018年6月收治的68例胃癌患者为对象,按电脑数字表法随机分为两组,对照组34例予以ECX方案(表柔比星+顺铂+卡培他滨)治疗,试验组34例予以FOLFIRI方案(伊立替康+氟尿嘧啶+甲酰四氢叶酸)治疗,对比两组有效率、IGF-1、VEGF、EGFR及CEA。结果：治疗后,试验组疾病控制率为61.76%,与对照组的58.82%比较差异无统计学意义(P＞0.05)；试验组患者IGF-1为(33.11±6.36)μg/L,VEGF为(260.66±50.15)ng/L,分别比对照组的(40.38±6.22)μg/L及(331.76±50.25)ng/L低,差异有统计学意义(P＜0.05)；试验组EGFR为(5.66±1.71)mg/L,CEA为(12.33±2.89)ng/L,分别比对照组的(10.38±1.89)mg/L及(20.11±2.59)ng/L低,差异有统计学意义(P＜0.05)。结论：FOLFIRI方案有助于提升胃癌患者疗效,并促使其IGF-1、VEGF、EGFR及CEA表达降低。 |
| 英文摘要: |
| SObjective:SAnalysis of the effects of FOLFIRI regimen on insulin-like growth factor-1(IGF-1), vascular endothelial growth factor(VEGF), epidermal growth factor receptor(EGFR) and carcinoembryonic antigen(CEA) in patients with gastric cancer. Methods: 68 casesSof gastric cancer patients wereSrandomly selected inSourShospital during January 2016 to June 2018, according to the computer digital table method, these patients were randomly divided into two groups, 34cases of patients in the control group were treated with ECX, and 34cases of patients in the experimental group were treated with FOLFIRI, the efficient, IGF-1, VEGF, EGFR and CEA were compared between the two groups. Results:SAfter treatment, the disease control rate in the experimental group was 61.76%, there was not statistically significant compared with the control group58.82% (P＞0.05). In the experimental group, the level of IGF-1 was(33.11±6.36)μg/L, the VEGF was (260.66±50.15)ng/L, which were lower than those in the control group(40.38±6.22)μg/L and (331.76±50.25)ng/L, respectively, with statistically significant (P<0.05). In the experimental group, the level of EGFR was(5.66±1.71)mg/L, the CEA was(12.33±2.89)ng/L, which were lower than those in the control group(10.38±1.89)mg/L and (20.11±2.59)ng/L, respectively, with statistically significant (P<0.05). Conclusion: FOLFIRI program can help to improve the efficacy of gastric cancer patients, as well as reduces the expression of IGF-1, VEGF, EGFR and CEA. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
